Landmark Success for Mitochondrial Donation: A Milestone for Families Worldwide
The birth of eight healthy babies in the UK through mitochondrial donation (also known as Mitochondrial Replacement Therapy) has been […]
Homepage News
IMP Announces New Board Following Election
IMP is delighted to announce the results of its recent Board elections, confirming a dynamic and diverse leadership team that
Scientists provide first evidence that the drug sildenafil may benefit patients with Leigh syndrome, and particularly those carrying mutations in the mitochondrial gene MT-ATP6.
Primary Mitochondrial Myopathies: Patient Journey
Navigating the journey to gain a diagnosis of Primary Mitochondrial Myopathy can be unnecessarily long, intensely stressful, and fraught with obstacles.
Collaboration with MITGEST
IMP is proud to support MITGEST. This international consortium brings together world-class academic experts in mitochondrial research.
SIMPATHIC project prepares to launch clinical trial
The SIMPATHIC project is preparing to launch a clinical trial using Sildenafil as a potential treatment for Leigh syndrome.
IMP joins UK MitoCohort Oversight Committee
IMP are delighted to have been asked to join the UK MitoCohort Oversight Committee. The UK Mitocohort is a UK wide database that collects clinical information on patients living with mito, to help advance understanding of the disease.
The PolG Foundation: Advancing Research and Hope for POLG Disorders
The PolG Foundation is committed to accelerating research efforts to develop effective treatments and, ultimately, a cure for POLG mitochondrial disorders.
LHON Awareness Day Webinar
During this year’s World Mitochondrial Disease Week, IMP hosted a free webinar on 19 September for LHON Awareness Day. The theme for the webinar was LHON and Gene Therapy: Where are they now?
Khondrion announces publication of results of integrated Phase 2b programme
On 7 November, biopharmaceutical company Khondrion announced the publication of results from their integrated Phase 2b clinical development programme which uses the drug sonlicromanol to target the underlying pathways of primary mitochondrial disease.